Solta Medical (NASDAQ: SLTM) and Accelerate Diagnostics (NASDAQ:AXDX) are both advanced medical equipment & technology – nec companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.


This table compares Solta Medical and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solta Medical N/A N/A N/A
Accelerate Diagnostics -3,085.36% -60.99% -57.85%

Analyst Ratings

This is a summary of recent ratings and target prices for Solta Medical and Accelerate Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solta Medical 0 0 0 0 N/A
Accelerate Diagnostics 0 0 2 0 3.00

Accelerate Diagnostics has a consensus target price of $33.00, indicating a potential upside of 56.03%.

Earnings and Valuation

This table compares Solta Medical and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Solta Medical N/A N/A N/A $0.02 N/A
Accelerate Diagnostics $250,000.00 4,686.84 -$66.37 million ($1.20) -17.62

Solta Medical has higher revenue, but lower earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Solta Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

44.4% of Accelerate Diagnostics shares are owned by institutional investors. 50.0% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Solta Medical

Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company’s systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company‚Äôs portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation. The Thermage system provides non-invasive skin tightening and the Liposonix system provides non-invasive body contouring. Isolaz and CLARO provide options to resolve acne. In January 2014, Valeant Pharmaceuticals International Inc ‘s wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Solta Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solta Medical Inc and related companies with's FREE daily email newsletter.